4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
Meet our experienced #Veristat Head of Global Medical Affairs, Atalah Haun, MD, at ESMO - European Society for Medical Oncology in Paris September 9 –13. Don´t miss the opportunity to discuss your clinical program with Veristat.
With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Whether you have a compound and need to get started on your IND, or want to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs - Veristat can help.
We provide impactful drug development and regulatory solutions on both a full-service or functional service basis.
Schedule a meeting with Atalah Haun, MD by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes.
Website: https://www.esmo.org/meetings/esmo-congress-2022/registrationhttps://informaconnect.com/bioeurope/
9th-13th September 2022 , Paris

4 min read
Jun 15, 2026 Veristat News
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
10 min read
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...